TELO
Telomir Pharmaceuticals, Inc.
0.5950
+0.02 (+2.73%)
52w low 0.5450
1.58 high
4.8% of range
Open
0.5870
High
0.7100
Low
0.5731
Prev Close
0.5792
Volume
321.15K
Avg Vol 3M
98.82K
Market Cap
43.84M
Currency
USD
6 Month Trend
—
C--
Chg--
Gap--
Vol--
×avg--
σ--
SMA20--
SMA50--
SMA200--
RSI--
SPY--
DD--
Bench--
Sig--
Hist--
pinned · Esc to release
hover · click to pin · ← → step · drag to zoom · shift-drag to measure
—Context
- Move across the chart.
Company
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| Employees | -- |
| Web | site ↗ |
Performance
1D
+4.02%
5D
-32.00%
1M
-45.91%
3M
-46.40%
6M
-51.63%
YTD
-55.26%
1Y
-58.10%
2Y
-86.42%
3Y
--
5Y
--
MAX
-93.44%
Valuation
| P/E Trailing | -- |
| P/E Forward | -2.13x |
| Price / Book | 3.46x |
| Price / Sales | -- |
| EV / EBITDA | -- |
| EPS Trailing | -0.96 |
| Dividend Yield | 0.00% |
| Beta | -0.19 |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -213.10% |
| Return on Assets | -122.81% |
| Revenue Growth | -- |
| Debt / Equity | 0.03x |
| Current Ratio | 16.14x |
Business
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.